2026-04-18T03:05:23Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/102202024-12-13T09:46:38Zcom_2072_378071com_2072_378040col_2072_378097

00925njm 22002777a 4500 dc Baldirà, Jaume author Ruiz Sanmartin, Adolfo author Cortes, Alejandro author Angeles Sistac, Diego author Comas, Inma author Villena-Ortiz, Yolanda author Larrosa-Garcia, Maria author Ruiz-Rodriguez, Juan Carlos author Chiscano Camon, Luis author Ferrer Costa, Roser author González-López, Juan José author Ferrer, Ricard author 2023-09-04T12:11:53Z 2023-09-04T12:11:53Z 2023-07-30 Molecular diagnosis; Mortality; Sepsis biomarkers Diagnóstico molecular; Mortalidad; Biomarcadores de sepsis Diagnòstic molecular; Mortalitat; Biomarcadors de sèpsia Early diagnosis and appropriate treatments are crucial to reducing mortality risk in septic patients. Low SOFA scores and current biomarkers may not adequately discern patients that could develop severe organ dysfunction or have an elevated mortality risk. The aim of this prospective observational study was to evaluate the predictive value of the biomarkers mid-regional pro-adrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate for 28-day mortality in patients with sepsis, and patients with a SOFA score ≤6. 284 were included, with a 28-day all-cause mortality of 8.45% (n = 24). Non-survivors were older (p = 0.003), required mechanical ventilation (p = 0.04), were ventilated for longer (p = 0.02), and had higher APACHE II (p = 0.015) and SOFA (p = 0.027) scores. Lactate showed the highest predictive ability for all-cause 28-day mortality, with an area under the receiver-operating characteristic curve (AUROC) of 0.67 (0.55–0.79). The AUROC for all-cause 28-day mortality in patients with community-acquired infection was 0.69 (0.57–0.84) for SOFA and 0.70 (0.58–0.82) for MR-proADM. A 2.1 nmol/L cut-off point for this biomarker in this subgroup of patients discerned, with 100% sensibility, survivors from non-survivors at 28 days. In patients with community-acquired sepsis and initial SOFA score ≤ 6, MR-proADM could help identify patients at risk of 28-day mortality. This research was funded by a restricted grant from Thermo Fisher (Hennigsdorf, Germany), consisting of free-of-charge kits. However, the funding organization had no role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. http://hdl.handle.net/11351/10220 Septicèmia - Diagnòstic Marcadors bioquímics Septicèmia - Mortalitat ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome::Sepsis Other subheadings::Other subheadings::Other subheadings::Other subheadings::/mortality TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica::sepsis Otros calificadores::Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA ≤ 6